Idioma:

Economic burden of sickle cell disease in Brazil

Silva-Pinto, Ana Cristina ; Costa, Fernando F ; Gualandro, Sandra Fatima Menosi ; Fonseca, Patricia Belintani Blum ; Grindler, Carmela Maggiuzzu ; Souza Filho, Homero C. R ; Bueno, Carolina Tosin ; Cançado, Rodolfo D Yassin, Mohamed A.

PloS one, 2022-06, Vol.17 (6), p.e0269703-e0269703 [Periódico revisado por pares]

San Francisco: Public Library of Science

Texto completo disponível

Citações Citado por

Enviar para

Título:
Economic burden of sickle cell disease in Brazil
Autor: Silva-Pinto, Ana Cristina ; Costa, Fernando F ; Gualandro, Sandra Fatima Menosi ; Fonseca, Patricia Belintani Blum ; Grindler, Carmela Maggiuzzu ; Souza Filho, Homero C. R ; Bueno, Carolina Tosin ; Cançado, Rodolfo D
Yassin, Mohamed A.
Assuntos: Adults ; Age groups ; Antibiotics ; Biology and Life Sciences ; Blood ; Blood transfusions ; Care and treatment ; Children ; Complications ; Cost estimates ; Costs ; Data analysis ; Economic aspects ; Evaluation ; Health care policy ; Hemoglobin ; Human capital ; Immunization ; Life expectancy ; Literature reviews ; Medical care, Cost of ; Medicine and Health Sciences ; Morbidity ; Mortality ; Mutation ; Patients ; People and places ; Productivity ; Sickle cell anemia ; Sickle cell disease ; Social Sciences ; Stem cell transplantation
É parte de: PloS one, 2022-06, Vol.17 (6), p.e0269703-e0269703
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
Descrição: Background Sickle cell disease (SCD) may cause several impacts to patients and the whole society. About 4% of the population has the sickle cell trait in Brazil, and 60,000 to 100,000 have SCD. However, despite recognizing the significant burden of disease, little is known about SCD costs. Objective To estimate SCD societal costs based on disease burden modelling, under Brazilian societal perspective. Methods A disease burden model was built considering the societal perspective and a one-year time horizon, including direct medical and indirect costs (morbidity and mortality). The sum of life lost and disability years was considered to estimate disability-adjusted life years (DALYs). Data from a public database (DATASUS) and the prevalence obtained from literature or medical experts were used to define complications prevalence and duration. Costs were defined using data from the Brazilian public healthcare system table of procedures and medications (SIGTAP) and the human capital method. Results Annual SCD cost was 413,639,180 USD. Indirect cost accounted for the majority of burden (70.1% of the total; 290,158,365 USD vs 123,480,816 USD). Standard of care and chronic complications were the main source of direct costs among adults, while acute conditions were the main source among children. Vaso-occlusive crisis represented the complication with the highest total cost per year in both populations, 11,400,410 USD among adults and 11,510,960 USD among children. Conclusions SCD management may impose an important economic burden on Brazilian society that may reach more than 400 million USD per year.
Editor: San Francisco: Public Library of Science
Idioma: Inglês

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Economic burden of sickle cell disease in Brazil

Silva-Pinto, Ana Cristina ; Costa, Fernando F ; Gualandro, Sandra Fatima Menosi ; Fonseca, Patricia Belintani Blum ; Grindler, Carmela Maggiuzzu ; Souza Filho, Homero C. R ; Bueno, Carolina Tosin ; Cançado, Rodolfo D Yassin, Mohamed A.

San Francisco: Public Library of Science

Buscando em bases de dados remotas. Favor aguardar.